These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17909093)

  • 1. Clinical experience with the addition of pramlintide in patients with insulin-requiring type 2 diabetes.
    Elkind-Hirsch K; Butler WJ; Bhushan M; Hirsch D; Bhushan R
    Diabetes Care; 2008 Jan; 31(1):39-40. PubMed ID: 17909093
    [No Abstract]   [Full Text] [Related]  

  • 2. Is pramlintide an adjunct to insulin therapy?
    Charles MA
    Diabetes Technol Ther; 2002; 4(2):190-2. PubMed ID: 12079622
    [No Abstract]   [Full Text] [Related]  

  • 3. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.
    Hollander P; Ratner R; Fineman M; Strobel S; Shen L; Maggs D; Kolterman O; Weyer C
    Diabetes Obes Metab; 2003 Nov; 5(6):408-14. PubMed ID: 14617226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
    Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
    Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
    Ratner RE; Dickey R; Fineman M; Maggs DG; Shen L; Strobel SA; Weyer C; Kolterman OG
    Diabet Med; 2004 Nov; 21(11):1204-12. PubMed ID: 15498087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.
    Karl D; Philis-Tsimikas A; Darsow T; Lorenzi G; Kellmeyer T; Lutz K; Wang Y; Frias JP
    Diabetes Technol Ther; 2007 Apr; 9(2):191-9. PubMed ID: 17425446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
    Ratner RE; Want LL; Fineman MS; Velte MJ; Ruggles JA; Gottlieb A; Weyer C; Kolterman OG
    Diabetes Technol Ther; 2002; 4(1):51-61. PubMed ID: 12017421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?
    Edelman SV; Garg S; Kolterman OG
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):E1; discussion E2. PubMed ID: 17452962
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.
    Maggs D; Shen L; Strobel S; Brown D; Kolterman O; Weyer C
    Metabolism; 2003 Dec; 52(12):1638-42. PubMed ID: 14669170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy.
    Peyrot M; Rubin RR; Polonsky WH
    Diabetes Technol Ther; 2008 Dec; 10(6):461-6. PubMed ID: 19049375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
    Ratner R; Whitehouse F; Fineman MS; Strobel S; Shen L; Maggs DG; Kolterman OG; Weyer C
    Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):199-204. PubMed ID: 15891954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
    Hollander P; Maggs DG; Ruggles JA; Fineman M; Shen L; Kolterman OG; Weyer C
    Obes Res; 2004 Apr; 12(4):661-8. PubMed ID: 15090634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amylin's pramlintide best of bad bunch of diabetes drugs.
    Brower V
    Nat Biotechnol; 1997 Oct; 15(10):935. PubMed ID: 9335036
    [No Abstract]   [Full Text] [Related]  

  • 15. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.
    Thompson RG; Pearson L; Schoenfeld SL; Kolterman OG
    Diabetes Care; 1998 Jun; 21(6):987-93. PubMed ID: 9614619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).
    Dharmalingam M; Kumar P
    J Assoc Physicians India; 2001 Jan; 49 Spec No():46-9. PubMed ID: 11235605
    [No Abstract]   [Full Text] [Related]  

  • 17. Are you up-to-date on diabetes medications?
    Scemons D
    Nursing; 2007 Jul; 37(7):45-9; quiz 49-50. PubMed ID: 17603373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
    Herrmann K; Frias JP; Edelman SV; Lutz K; Shan K; Chen S; Maggs D; Kolterman OG
    Postgrad Med; 2013 May; 125(3):136-44. PubMed ID: 23748514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk.
    Hoogwerf BJ; Doshi KB; Diab D
    Vasc Health Risk Manag; 2008; 4(2):355-62. PubMed ID: 18561511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.
    Thompson RG; Gottlieb A; Organ K; Koda J; Kisicki J; Kolterman OG
    Diabet Med; 1997 Jul; 14(7):547-55. PubMed ID: 9223392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.